Q4 2025 Holdings
Filed 2026-02-17 | 43 holdings | $3.0B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Abivax SA American Depositary Shares(ABVX) | ADRS | 00370M103 | $959.0M | 7,111,596 | 31.7% |
| Cogent Biosciences Inc(COGT) | COMM | 19240Q201 | $208.4M | 5,868,162 | 6.9% |
| CG Oncology Inc(CGON) | COMM | 156944100 | $152.4M | 3,670,206 | 5.0% |
| Tango Therapeutics Inc(TNGX) | COMM | 87583X109 | $113.1M | 12,762,094 | 3.7% |
| Centessa Pharmaceuticals PLC(CNTA) | ADRS | 152309100 | $107.2M | 4,286,480 | 3.5% |
| Dyne Therapeutics Inc(DYN) | COMM | 26818M108 | $90.3M | 4,615,144 | 3.0% |
| Rapt Therapeutics Inc(RAPT) | COMM | 75382E208 | $87.5M | 2,582,408 | 2.9% |
| Tyra Biosciences Inc(TYRA) | COMM | 90240B106 | $76.2M | 2,898,103 | 2.5% |
| Amylyx Pharmaceuticals Inc(AMLX) | COMM | 03237H101 | $75.4M | 6,243,812 | 2.5% |
| Savara Inc(SVRA) | COMM | 805111101 | $74.5M | 12,362,205 | 2.5% |
| Monte Rosa Therapeutics Inc(GLUE) | COMM | 61225M102 | $72.5M | 4,622,151 | 2.4% |
| Ocular Therapeutix Inc(OCUL) | COMM | 67576A100 | $69.7M | 5,740,231 | 2.3% |
| Dianthus Therapeutics Inc(DNTH) | COMM | 252828108 | $69.1M | 1,676,624 | 2.3% |
| Eyepoint Pharmaceuticals Inc(EYPT) | COMM | 30233G209 | $65.3M | 3,572,335 | 2.2% |
| Structure Therapeutics Inc(GPCR) | ADRS | 86366E106 | $64.0M | 920,857 | 2.1% |
| Spyre Therapeutics Inc(SYRE) | COMM | 00773J202 | $62.3M | 1,900,582 | 2.1% |
| Fulcrum Therapeutics Inc(FULC) | COMM | 359616109 | $59.4M | 5,250,000 | 2.0% |
| Liquidia Technologies Inc(LQDA) | COMM | 53635D202 | $59.0M | 1,710,084 | 2.0% |
| Biohaven LTD(BHVN) | COMM | G1110E107 | $52.3M | 4,631,317 | 1.7% |
| Immunovant Inc(IMVT) | COMM | 45258J102 | $42.2M | 1,660,933 | 1.4% |
| Kodiak Sciences Inc(KOD) | COMM | 50015M109 | $40.4M | 1,445,538 | 1.3% |
| ADC Therapeutics SA(ADCT) | COMM | H0036K147 | $40.2M | 11,390,175 | 1.3% |
| LB Pharmaceuticals Inc(LBRX) | COMM | 50180M108 | $38.8M | 1,745,015 | 1.3% |
| Xencor Inc(XNCR) | COMM | 98401F105 | $37.5M | 2,452,138 | 1.2% |
| Revolution Medicines Inc(RVMD) | COMM | 76155X100 | $34.8M | 436,473 | 1.2% |
| Agios Pharmaceuticals Inc(AGIO) | COMM | 00847X104 | $32.2M | 1,181,841 | 1.1% |
| Arvinas Holding Co LLC(ARVN) | COMM | 04335A105 | $31.6M | 2,666,216 | 1.0% |
| Relay Therapeutics Inc(RLAY) | COMM | 75943R102 | $27.2M | 3,220,186 | 0.9% |
| Janux Therapeutics Inc(JANX) | COMM | 47103J105 | $24.7M | 1,789,617 | 0.8% |
| Entrada Therapeutics Inc(TRDA) | COMM | 29384C108 | $21.5M | 2,088,392 | 0.7% |
| MBX Biosciences Inc(MBX) | COMM | 55287L101 | $20.5M | 650,000 | 0.7% |
| Upstream BIO Inc(UPB) | COMM | 91678A107 | $20.2M | 743,886 | 0.7% |
| Silence Therapeutics PLC(SLN) | ADRS | 82686Q101 | $18.4M | 3,033,560 | 0.6% |
| Urogen Pharma LTD(URGN) | COMM | M96088105 | $16.8M | 717,347 | 0.6% |
| Alector Inc(ALEC) | COMM | 014442107 | $15.6M | 10,000,000 | 0.5% |
| Monopar Therapeutics Inc(MNPR) | COMM | 61023L207 | $9.3M | 141,915 | 0.3% |
| Avalo Therapeutics Inc(AVTX) | COMM | 05338F306 | $8.8M | 483,000 | 0.3% |
| Maze Therapeutics Inc(MAZE) | COMM | 578784100 | $7.2M | 173,816 | 0.2% |
| Mirum Pharmaceuticals Inc(MIRM) | COMM | 604749101 | $4.9M | 62,049 | 0.2% |
| Athira Pharma, Inc.(LONA) | COMM | 04746L203 | $3.3M | 464,398 | 0.1% |
| Korro BIO Inc(KRRO) | COMM | 500946108 | $3.3M | 416,301 | 0.1% |
| Ventyx Biosciences Inc(VTYX) | COMM | 92332V107 | $2.9M | 316,195 | 0.1% |
| Vistagen Therapeutics Inc(VTGN) | COMM | 92840H400 | $1.8M | 2,676,580 | 0.1% |